Correlation Between Brainstorm Cell and Protalix Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Brainstorm Cell and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Brainstorm Cell and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Brainstorm Cell Therapeutics and Protalix Biotherapeutics, you can compare the effects of market volatilities on Brainstorm Cell and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Brainstorm Cell with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Brainstorm Cell and Protalix Biotherapeutics.

Diversification Opportunities for Brainstorm Cell and Protalix Biotherapeutics

-0.63
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Brainstorm and Protalix is -0.63. Overlapping area represents the amount of risk that can be diversified away by holding Brainstorm Cell Therapeutics and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Brainstorm Cell is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Brainstorm Cell Therapeutics are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Brainstorm Cell i.e., Brainstorm Cell and Protalix Biotherapeutics go up and down completely randomly.

Pair Corralation between Brainstorm Cell and Protalix Biotherapeutics

Given the investment horizon of 90 days Brainstorm Cell Therapeutics is expected to under-perform the Protalix Biotherapeutics. In addition to that, Brainstorm Cell is 1.41 times more volatile than Protalix Biotherapeutics. It trades about -0.2 of its total potential returns per unit of risk. Protalix Biotherapeutics is currently generating about 0.19 per unit of volatility. If you would invest  107.00  in Protalix Biotherapeutics on September 3, 2024 and sell it today you would earn a total of  65.00  from holding Protalix Biotherapeutics or generate 60.75% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Brainstorm Cell Therapeutics  vs.  Protalix Biotherapeutics

 Performance 
       Timeline  
Brainstorm Cell Ther 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Brainstorm Cell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.
Protalix Biotherapeutics 

Risk-Adjusted Performance

15 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Brainstorm Cell and Protalix Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Brainstorm Cell and Protalix Biotherapeutics

The main advantage of trading using opposite Brainstorm Cell and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Brainstorm Cell position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.
The idea behind Brainstorm Cell Therapeutics and Protalix Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Complementary Tools

Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
CEOs Directory
Screen CEOs from public companies around the world
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance